05-08 19:51
炸裂也算不上吧。血液瘤商业化能力还是挺强的。
The U.S. Patent and Trademark Office (USPTO) granted the Company’s petition for post-grant review of the Pharmacyclics’ patent asserted against the Company in a patent infringement suit, stating that the Company has shown that it is more likely...
炸裂也算不上吧。血液瘤商业化能力还是挺强的。